Value through Innovation27 July 2016

Clinical Study Results

  • BIWH 3 - Peripheral Arterial Disease
    Clinical Study Number 1181.1
    Study Indication Peripheral Arterial Disease
    Product BIWH 3
    Generic Name BIWH 3
    Lab Code
    Clinical Phase I
    Study Title

    A randomised, double-blind, placebo-controlled, dose escalation study to investigate safety, pharmacokinetics and pharmacodynamics of different doses (0.2, 0.6, 2.0, 6.0, and 20.0 µg/hr) of BIWH 3 administered for 6 hours in patients with chronic Critical Limb Ischaemia (CLI, Fontaine class III or IV). COINART-1 trial (first COllateral INto ARTery Trial)

    Study Document Trial synopsis 1181.1_CO english
  • BIWH 3 - Healthy
    Clinical Study Number 1181.2
    Study Indication Healthy
    Product BIWH 3
    Generic Name BIWH 3
    Lab Code
    Clinical Phase I
    Study Title

    Pharmacokinetics and Pharmacodynamics of BIWH 3: a randomised, placebo-controlled, double-blind dose escalation study (0.02, 0.06, 0.2,0.6, and 2.0 µg/kg intravenous over one hour) in healthy Duffy positive vs. Duffy negative male volunteers.

    Study Document Trial synopsis 1181.2_CO english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.